Based on these molecular hubs, this study proposes three translational pathways: 1 Develop early diagnostic markers for Osteoporosis-stroke comorbidity based on gene expression profiles such as LILRA5; 2 Shorten the R&D cycle through repositioning old drugs (e.g., Cyclopenthiazide targeting vascular calcification and bone metabolism); 3 Design combination therapies targeting AGBL3/HNRNPL to achieve “one drug for two diseases.” Subsequent research could expand target exploration through multi-omics integration (epigenome + proteome) and validate cross-organ efficacy using organoid models. Here, AGBL3 is linked to osteoporosis.